NOAH Compendium

Printed from NOAH Compendium ( (c) Copyright NOAH Compendium 2022. All Rights Reserved.
Date: Saturday, May 21, 2022 5:28

Description: MSD-AH
Release 2.74
Porcilis® Glässer Suspension for injection for pigs
Species: Pigs
Therapeutic indication: Immunological veterinary medical products: For pigs
Active ingredient: Vaccine Antigens
Product:Porcilis® Glässer Suspension for injection for pigs
Product index: Porcilis® Glässer
Pig - meat: Zero days
Qualitative and quantitative composition
Active substance(s) per dose of 2 ml: Inactivated whole bacterial cells of Haemophilus parasuis serotype 5, strain 4800: 0.05 mg total nitrogen, inducing ≥ 9.1 Elisa Units*.
Adjuvant: 150 mg dl-α-tocopheryl acetate.
Excipients: For a full list of excipients, see section Pharmaceutical Particulars.
* ELISA units = mean antibody titre (log2 value) in the potency test in mice.
Pharmaceutical form
Suspension for injection.
Appearance: aqueous, white or nearly white suspension.
Clinical particulars
Target species
Pigs and sows
Indications for use
Active immunisation of pigs to reduce typical lesions of Glässer’s disease caused by Haemophilus parasuis serotype 5.
Onset of immunity: 2 weeks after completion of vaccination.
Duration of immunity: 14 weeks after completion of vaccination.
For passive immunisation of the progeny of vaccinated sows and gilts to reduce infection, mortality, clinical signs and typical lesions of Glässer disease caused by Haemophilus parasuis serotype 5 and to reduce clinical signs and mortality caused by Haemophilus parasuis serotype 4.
Onset of immunity: After birth and sufficient uptake of colostrum.
Duration of immunity has been demonstrated at 4 weeks of age against serotype 4 and at 6 weeks of age against serotype 5.
Special warnings for each target species
Special precautions for use
Vaccinate only healthy animals. In the event of anaphylactic reaction consult your veterinarian.
Operator warnings
In case of accidental self-injection, seek medical advice immediately and show the package leaflet or the label to the physician.
Adverse reactions
Pigs: A transient increase in temperature (≤ 2 °C) in combination with signs of general discomfort, such as less activity, depression and vomiting may occur on the day of vaccination. The next day the animals are back to normal. Local reactions (painless reddish swellings of 2.5-7.5 cm) may be observed in some pigs until 3 days after vaccination. Systemic anaphylactic reactions may occur in very rare cases (e.g. less than 1 animal in 10,000 animals).
Sows: A transient increase in temperature may occur (mean 0.9 °C, with individual animals displaying a temperature increase of above 2 °C). A tendency to lie down, reduced feed and water intake and minor signs of illness may be observed 1 to 2 days after vaccination. All animals return to normal within 1 to 3 days after vaccination. Transient local reactions consisting mostly of non-painful swellings with a diameter smaller than 10 cm may be observed. In some cases swelling may be warm, red and painful with a size larger than 10 cm. These local reactions disappear or clearly diminish 14 days after vaccination.
Use during pregnancy or lactation
Can be used during pregnancy.
No information is available on the compatibility of this vaccine with any other. Therefore the safety and efficacy of this product when used with any other (either when used on the same day or at different times) has not been demonstrated.
Amounts to be administered and administration route
Allow vaccine to reach ambient temperature. Shake well before use. Administer 2 ml (one dose) of the vaccine intramuscularly in the neck of the pig.The vaccine is of benefit when pigs and sows with no or low levels of antibodies against H. parasuis serotype 5 are mixed with animals from or in an environment with higher prevalence of Glässers disease or if the piglets from sows with no or low antibodies are reared in such environment. Vaccination of sows with moderate to high levels of antibodies has not been shown to provide additional protection of the offspring. The control of Glässers disease is also dependent on management factors and reduction of stress. Antibodies against H. parasuis serotype 5 have been shown to be cross-reactive against H. parasuis serotype 4.
Vaccination scheme pigs: Vaccinate pigs of at least five weeks of age twice with an interval of two weeks.
Vaccination scheme sows: Vaccinate sows at 6 to 8 weeks before expected time of farrowing twice with an interval of four weeks.
Revaccination scheme sows: For sows vaccinated during the previous pregnancy, a single revaccination at 4 to 2 weeks before farrowing is recommended.
Pigs: After vaccination with a twofold overdose, reactions are not different from those after the single dose. Sows: After vaccination with a twofold overdose, a transient increase in temperature may occur (mean 1.8 °C, with a maximum observed temperature of 41.3°C). Other reactions are not different from those after a single dose.
Withdrawal period
Zero days.
Pharmacological particulars
ATC vet code: QI 09AB07.
Pharmacotherapeutic group
Inactivated bacterial vaccine.
The product stimulates the development of active immunity against Haemophilus parasuis serotype 5. Serotype 5 is the most prevalent under the virulent serotypes of H. parasuis. There is some cross protection to the other virulent serotypes, but full cross protection cannot be assured. The product stimulates transfer of passive immunity against Haemophilus parasuis serotype 5 and 4 to the progeny after vaccination of pregnant sows. It contains an aqueous adjuvant.
Pharmaceutical particulars
Phosphate buffer
Water for injections
Polysorbate 80.
Major incompatibilities
Do not mix with any other vaccine or immunological product.
Shelf life
Shelf-life of the veterinary medicinal product as packaged for sale
PET vials: 3 years Glass vials: 1 year
Shelf-life after first opening the immediate packaging
Use broached vials immediately.
Special precautions for storage
Store in a refrigerator (2°C - 8°C). Do not freeze. Protect from light.
Immediate packaging
Vials of PET or Glass type I (Ph. Eur.) containing 20 ml (10 dose presentation), 50 ml (25 dose presentation) or 100 ml (50 dose presentation), closed with a halogenobutyl rubber stopper and sealed with a coded aluminium cap. Porcilis Glässer is presented in cartons containing 1, 6 or 12 vials of 20 ml, 50 ml or 100 ml. Not all pack sizes may be marketed
Any unused product or waste material should be disposed of in accordance with national requirements.
Marketing Authorisation Holder (if different from distributor)
Marketing Authorisation Number
UK: Vm 01708/4634
Significant changes
Date of the first authorisation or date of renewal
30 March 2008.
Date of revision of the text
March 2022.
Any other information
For animal treatment only. Keep out of the sight and reach of children.
Legal category
Legal category: POM-V
GTIN description:Porcilis Glasser 1x50ml: